Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C-type lectin-like receptor CD161 (CD161)
- Target
- CD161
- Molecular classification
- C-type lectin-like receptor, Type II transmembrane protein
01
Overview
CD161 is a type II transmembrane C-type lectin-like receptor expressed on various lymphocyte populations, including NK cells and subsets of T cells. It functions as a marker for innate-like T cells and IL-17-producing T helper (Th17) cells. Its interaction with its ligand LLT1 modulates immune responses, particularly inhibiting NK cell cytotoxicity. CD161 is implicated in chronic inflammation, autoimmunity, viral infection, and cancer, making it a potential therapeutic target. However, its complex and sometimes contradictory functions in different immune cell types pose challenges for therapeutic development.
- Other names
- Killer Cell Lectin-Like Receptor Subfamily B, Member 1KLRB1
02
Mechanism of action
Modulation of immune cell activity via LLT1 interaction.
03
Biological functions
Immune response modulationRegulation of NK cell cytotoxicityCytokine production (IL-17, IL-22, IFNγ)Cell signaling
04
Disease associations
AutoimmunityChronic inflammationViral infectionCancer
05
Safety considerations
Potential for immune dysregulation due to broad expression on immune cells.Unclear signaling function in T cells makes targeted therapies challenging.
06
Biomarkers
CD161 expression on T cells as a marker for Th17 cellsCD161 expression on NK cells as a marker for maturation and cytotoxicity
Beyond the preview
Go deeper on C-type lectin-like receptor CD161 (CD161).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C-type lectin-like receptor CD161 (CD161).